MODEL VERDICT
AstraZeneca PLC (AZN)
Relative Valuation•Peer multiples, competitive benchmarking & quality-adjusted fair value
The market is pricing AstraZeneca PLC at a 22.2% premium to its peer-implied fair value.
7 curated peers matched by business model, revenue composition, and market position
4 valuation metrics · peer-median based
| Multiple | Current | Peer Median | vs Peers | Implied Price |
|---|---|---|---|---|
| Forward P/EPrice paid for next year's expected earnings. | 17.01x | 15.21x | Premium +11.88% | $156.36 |
| P/EPrice paid for current earnings. | 26.75x | 18.54x | Premium +44.24% | $123.42 |
| EV/EBITDAEnterprise value versus operating cash earnings proxy. | 15.16x | 10.82x | Premium +40.11% | $124.99 |
| P/FCFPrice paid for free cash flow. | 23.05x | 15.87x | Premium +45.27% | $119.52 |
How the model derives the final fair value from peer baselines and quality metrics
Premium: The stock is trading at a 28.53% premium to its quality-adjusted fair value of $136.10. The market is pricing the stock 22.2% above our model's estimate.
Quality metrics are broadly comparable to peers.
Quality adjustments are capped at ±15% (up to ±20% for financial services) to prevent runaway premiums. Based on trailing twelve months and multi-year CAGR data where available.
How current multiples rank vs 8 years of the stock’s own history
| Multiple | Current | Historical Median | Percentile | Status |
|---|---|---|---|---|
| P/E7 years of data | 26.75x | 43.18x | 0th | Below historical norm |
| EV/EBITDA8 years of data | 15.16x | 17.87x | 25th | Below historical norm |
| P/FCF7 years of data | 23.05x | 31.98x | 0th | Below historical norm |
AstraZeneca PLC currently trades near the lowest valuation levels observed during the last 8 years.
Wall Street target prices — 41 analysts
Model-identified caveats to consider
AZN looks expensive versus peers using AI-curated peers, with relative upside of -22.2%.
Answers to common questions about AZN's relative valuation and our methodology.
AstraZeneca PLC's fair value of $136.10 is the price at which the stock would trade if valued at the same multiples as its 7-company peer group, adjusted for differences in business quality. At $174.93, the stock trades at a -22.2% premium to fair value. This is a reference point, not a price target.
The 7 peers shown were selected based on business model similarity, revenue composition, and market position. Each peer was matched for comparable operations, not just industry label. Only companies with clean, usable financial data are included.
AstraZeneca PLC has strengths in 3y revenue growth, 3y eps growth, net debt / ebitda, and challenges in roic, fcf margin, and a quality score that justifies a 2.4% premium relative to its peer group. The Quality Adjustment section breaks down each driver.
No. This page provides an automated quantitative comparison of AstraZeneca PLC against its peers. It is not investment advice, a recommendation, or a solicitation. Valuation is only one factor in an investment decision — it does not account for growth catalysts, management quality, regulatory risk, or your personal financial situation.
Look at the Historical Context to see where current multiples sit versus the stock's own history. Review the Risk Factors section for model-identified caveats. Compare the Analyst Consensus to our model output for another perspective. Valuation is only one dimension — growth trajectory, competitive position, and market conditions all matter.
Valuation data is refreshed weekly based on the latest financial filings, market prices, and analyst estimates. AstraZeneca PLC's fair value, peer multiples, and quality scores will shift over time as new earnings are reported and stock prices change.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. Fair value estimates are model outputs under stated assumptions and should not be relied upon as the sole basis for any investment decision.